RDY Quote, Financials, Valuation and Earnings

ICICI Bank has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of 25.53%. Dr Reddy's Laboratories's return on equity of 19.35% beat ICICI Bank's return on equity of 17.65%.

Dr Reddy's Laboratories has a consensus price target of $14.11, signalling upside risk potential of 0.85%. On the other hand ICICI Bank has an analysts' consensus of -- which suggests that it could grow by 19.47%. Given that ICICI Bank has higher upside potential than Dr Reddy's Laboratories, analysts believe ICICI Bank is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.533, which suggesting that the stock is 46.687% less volatile than S&P 500. In comparison ICICI Bank has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.083999999999995%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.62%. ICICI Bank offers a yield of 0.79% to investors and pays a quarterly dividend of $0.24 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. ICICI Bank pays out 12.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $956.9M, which are smaller than ICICI Bank quarterly revenues of $6.1B. Dr Reddy's Laboratories's net income of $149.8M is lower than ICICI Bank's net income of $1.5B. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 32.94x while ICICI Bank's PE ratio is 19.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.65x versus 4.95x for ICICI Bank. Usually stocks with elevated PS ratios are considered overvalued.

SS Innovations International has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of --. Dr Reddy's Laboratories's return on equity of 19.35% beat SS Innovations International's return on equity of --.

Dr Reddy's Laboratories has a consensus price target of $14.11, signalling upside risk potential of 0.85%. On the other hand SS Innovations International has an analysts' consensus of -- which suggests that it could fall by --. Given that Dr Reddy's Laboratories has higher upside potential than SS Innovations International, analysts believe Dr Reddy's Laboratories is more attractive than SS Innovations International.

Dr Reddy's Laboratories has a beta of 0.533, which suggesting that the stock is 46.687% less volatile than S&P 500. In comparison SS Innovations International has a beta of -54.576, suggesting its less volatile than the S&P 500 by 5557.55%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.62%. SS Innovations International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. SS Innovations International pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than SS Innovations International quarterly revenues of --. Dr Reddy's Laboratories's net income of $149.8M is higher than SS Innovations International's net income of --. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 32.94x while SS Innovations International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.65x versus -- for SS Innovations International. Usually stocks with elevated PS ratios are considered overvalued.

111 has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of -0.48%. Dr Reddy's Laboratories's return on equity of 19.35% beat 111's return on equity of -89.07%.

Dr Reddy's Laboratories has a consensus price target of $14.11, signalling upside risk potential of 0.85%. On the other hand 111 has an analysts' consensus of -- which suggests that it could grow by 582.29%. Given that 111 has higher upside potential than Dr Reddy's Laboratories, analysts believe 111 is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.533, which suggesting that the stock is 46.687% less volatile than S&P 500. In comparison 111 has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.65%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.62%. 111 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. 111 pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than 111 quarterly revenues of $502.9M. Dr Reddy's Laboratories's net income of $149.8M is higher than 111's net income of -$2.4M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 32.94x while 111's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.65x versus 0.04x for 111. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of 15.66% compared to Dr Reddy's Laboratories's net margin of -40.75%. Dr Reddy's Laboratories's return on equity of 19.35% beat Zai Lab's return on equity of -35.53%.

Dr Reddy's Laboratories has a consensus price target of $14.11, signalling upside risk potential of 0.85%. On the other hand Zai Lab has an analysts' consensus of $52.39 which suggests that it could grow by 95.93%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.533, which suggesting that the stock is 46.687% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.054%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.62%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.94% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $956.9M, which are larger than Zai Lab quarterly revenues of $102.3M. Dr Reddy's Laboratories's net income of $149.8M is higher than Zai Lab's net income of -$41.7M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 32.94x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.65x versus 7.33x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.